Drug Profile
Interleukin-1-alpha
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Unknown
- Developer Nonindustrial source
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin 1-alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Peptic ulcer; Transplant rejection
Most Recent Events
- 04 Nov 1996 Preclinical development for Transplant rejection in USA (Unknown route)
- 24 Apr 1995 Preclinical development for Bacterial infections in USA (Unknown route)
- 24 Apr 1995 Preclinical development for Peptic ulcer in Japan (Unknown route)